Does Enanta’s EU Lawsuit Over Paxlovid Shift the Bull Case for Pfizer (PFE)?

Enanta Pharmaceuticals has filed a patent infringement lawsuit against Pfizer and subsidiaries in the Unified Patent Court of the European Union, alleging that Pfizer’s COVID-19 antiviral Paxlovid infringes newly granted European Patent No. EP 4 051 265 across 18 EU countries. This legal challenge introduces significant uncertainty around a key revenue driver for Pfizer and comes as investor attention remains elevated due to both fundamental performance and shifting sentiment indicators. Given the increased legal risk facing Paxlovid, we’ll now examine how this development impacts Pfizer’s investment narrative and risk outlook.

Outshine the giants: these 22 early-stage AI stocks could fund your retirement.

Pfizer Investment Narrative Recap

To own Pfizer shares today, you generally need to believe in the company’s ability to manage through competitive and regulatory pressures while offsetting upcoming patent expirations by successfully launching new therapies and executing on its pipeline. The Enanta lawsuit over Paxlovid is an incremental legal risk to a current key revenue stream, but based on what’s been disclosed, it does not fundamentally alter the biggest catalysts, late-stage pipeline results and new product launches, or the principal risk, which remains future patent cliffs on major drugs.

Among recent announcements, Pfizer’s positive Q2 2025 financials stand out: revenue and net income were up year-over-year, with updated annual guidance reaffirming a high-single-digit billion dollar range despite COVID-19 headwinds. While legal pressures like the Enanta lawsuit are meaningful, the near-term focus for many investors remains pipeline progress and new drug approvals, such as positive phase 3 data for PADCEV in combination with KEYTRUDA in muscle-invasive bladder cancer.

In contrast, investors should keep in mind one area that could impact Pfizer’s future margins but remains less discussed in the context of these legal disputes...

Read the full narrative on Pfizer (it's free!)

Pfizer's outlook anticipates $59.7 billion in revenue and $13.2 billion in earnings by 2028. This scenario involves a yearly revenue decline of 2.2% and a $2.5 billion increase in earnings from today's $10.7 billion.

Uncover how Pfizer's forecasts yield a $28.77 fair value, a 15% upside to its current price.

Exploring Other PerspectivesPFE Community Fair Values as at Aug 2025

Some of the most optimistic analysts were forecasting Pfizer could deliver up to US$16.6 billion in earnings and US$65.7 billion in revenue by 2028, hinging growth on rapid regulatory progress and emerging market momentum. Compared to consensus, these outlooks reflect a much more positive narrative on pipeline execution and international expansion. Remember, forecasts can shift quickly as news like the recent Enanta lawsuit emerges, so it’s important to consider a range of opinions when evaluating the stock.

Story Continues

Explore 32 other fair value estimates on Pfizer - why the stock might be worth just $24.00!

Build Your Own Pfizer Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

A great starting point for your Pfizer research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision. Our free Pfizer research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Pfizer's overall financial health at a glance.

Seeking Other Investments?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

The end of cancer? These 26 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's. We've found 19 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. AI is about to change healthcare. These 27 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include PFE.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments